Bionano Genomics (BNGO) Net Cash Flow (2017 - 2026)

Bionano Genomics has disclosed Net Cash Flow across 10 years of filings, most recently posting $398000.0 for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $398000.0, up 106.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 110.24% YoY), and the FY2025 annual result was -$5.1 million, up 42.37% from the prior year.
• Net Cash Flow came in at $398000.0 for Q1 2026 at Bionano Genomics, down from $1.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $19.7 million in Q3 2023 to a low of -$22.8 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$88000.0 (2025), against an average of -$1.2 million.
• Across the five-year window, Net Cash Flow jumped 1643.77% in 2023 and sank 174.57% in 2025, its largest moves.
• Bionano Genomics' Net Cash Flow stood at -$22.8 million in 2022, then gained by 26.77% to -$16.7 million in 2023, then jumped by 102.3% to $383000.0 in 2024, then soared by 283.03% to $1.5 million in 2025, then tumbled by 72.87% to $398000.0 in 2026.
• The last three Net Cash Flow figures came in at $398000.0 (Q1 2026), $1.5 million (Q4 2025), and -$493000.0 (Q3 2025), per Business Quant data.